David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Advies: uitbreiding vergoeding axicabtagene ciloleucel (Yescarta) voor behandeling lymfeklierkanker
jun 2024 | Lymfoom